Breaking News

European Court Orders Russia to Pay €1.87 Billion for Yukos Seizure
Tweet TWEET

MERCK SERONO ANNOUNCES US FDA APPROVAL FOR FERTILITY PEN (ENG)

     (The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Bettina Frank
Phone +49 6151 72-4660 
Merck Serono Announces US FDA Approval for Fertility Pen 
• Gonal-f® RFF Redi-jectTM (follitropin alfa injection) redesigned to
  incorporate patient and provider feedback 
Darmstadt, Germany, October 18, 2013 - Merck Serono, the biopharmaceutical
division of Merck, today announced that the U.S. Food and Drug
Administration (FDA) granted approval to its subsidiary, EMD Serono, Inc.,
for Gonal-f® RFF Redi-ject™ (follitropin alfa injection), a disposable
pre-filled drug injector pen intended for the subcutaneous injection of a
liquid formulation of Gonal-f® RFF (Revised Formulation Female). 
The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/5984B5487B5D4240C1257C080052D73C/$File/PR_Gonal_FDA_e.p
df 
News releases from Merck KGaA, Darmstadt, Germany, are available at this
address:
www.merckgroup.com/media or for residents in the USA and Canada at
www.emdgroup.com/media 
In case you are a resident of the USA or Canada please go to
http://www.emdgroup.com/subscribe to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
You may change your subscription at any time by following either one of the
following links:
www.merckgroup.com/subscribe or www.emdgroup.com/subscribe
And please feel free to unsubscribe this service with either
www.merckgroup.com/subscribe or www.emdgroup.com/unsubscribe
Thank you very much! 
Merck KGaA ,Darmstadt, Germany
External Communications
E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
therewith. 
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.